- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07527741
Tutkimus, jossa arvioidaan hoitokäytäntöjä ja hoidon noudattamista varhaisen HER2-positiivisen rintasyövän osallistujilla hoidon hajauttamisen jälkeen (Close2HER)
Todellisen maailman tutkimus hoitokäytänteistä ja hoitoon sitoutumisesta varhaisvaiheen HER2-positiivisessa rintasyövässä Serbiassa hoidon hajauttamisen jälkeen (Close2HER)
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Tutki yhteystietojen varmuuskopiointi
- Nimi: Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
- Puhelinnumero: 888-662-6728 (U.S. Only)
- Sähköposti: global-roche-genentech-trials@gene.com
Opiskelupaikat
-
-
Bolnička 65
-
Loznica, Bolnička 65, Serbia, 15300
- Rekrytointi
- Health Centre Loznica
-
-
Bratstva Jedinstva 135
-
Požarevac, Bratstva Jedinstva 135, Serbia, 12000
- Rekrytointi
- General Hospital Požarevac
-
-
Dragiše Mišovića 1
-
Bor, Dragiše Mišovića 1, Serbia, 19210
- Rekrytointi
- Healthcare Centre Bor
-
-
Dunavska 1-3
-
Kladovo, Dunavska 1-3, Serbia, 19320
- Rekrytointi
- Health Centre Kladovo
-
-
Knez Mihailova 51
-
Smederevo, Knez Mihailova 51, Serbia, 11300
- Rekrytointi
- Health Centre ''Sveti Luka'' Smederevo
-
-
Miloša Trebinjca 11
-
Pančevo, Miloša Trebinjca 11, Serbia, 26000
- Rekrytointi
- General Hospital Pančevo
-
-
Pasterova 14
-
Belgrade, Pasterova 14, Serbia, 11000
- Rekrytointi
- Institute for Onocology and Radiology of Serbia
-
-
Popa Karana 2-4
-
Šabac, Popa Karana 2-4, Serbia, 15000
- Rekrytointi
- General Hospital "Dr Laza K. Lazarevic" Sabac
-
-
Sinđelićeva 62
-
Valjevo, Sinđelićeva 62, Serbia, 14000
- Rekrytointi
- Health Centre Valjevo
-
-
Vuka Karadžića 147
-
Smederevska Palanka, Vuka Karadžića 147, Serbia, 11420
- Rekrytointi
- General Hospital ''Stefan Visoki'' Smederevska Palanka
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.
Kuvaus
Inclusion Criteria:
- Diagnosis of stage II and III HER2+ eBC according to European Society For Medical Oncology (ESMO) guidelines
- Underwent curative-intent surgical resection for BC
- Histologically documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery
Exclusion Criteria:
- Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide informed consent or to complete study-related questionnaires
- Receipt of prior neoadjuvant or adjuvant therapy for HER2+ BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
- Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Group 1: Cohort A
Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 2: Cohort B
Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort C
Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort D
Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Hoitoon Sitoutumisen Määrä
Aikaikkuna: Jopa 2,25 vuotta
|
Jopa 2,25 vuotta
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Anti-HER2-hoidon hoitoprosessin suoritusprosentti
Aikaikkuna: Jopa 2,25 vuotta
|
Jopa 2,25 vuotta
|
|
|
Osallistujien prosenttiosuus, joilla on ≥1 annoksen viivästystä ennalta määritellyn rajan (3 viikkoa) ylittävästi suunnitellusta päivämäärästä
Aikaikkuna: Jopa 2,25 vuotta
|
Jopa 2,25 vuotta
|
|
|
Aika adjuvanssilääkityksen aloittamiseen
Aikaikkuna: Aika leikkauksesta adjuvanttihoidon aloittamiseen (noin 1,25 vuoteen)
|
Aika leikkauksesta adjuvanttihoidon aloittamiseen (noin 1,25 vuoteen)
|
|
|
Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase
Aikaikkuna: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers [km]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires. |
Up to 2.25 years
|
|
Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers
Aikaikkuna: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase. |
Up to 2.25 years
|
|
Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C
Aikaikkuna: At 6 months post-baseline
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL). |
At 6 months post-baseline
|
|
Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score
Aikaikkuna: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL. |
Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
|
Time to Neoadjuvant Treatment Initiation
Aikaikkuna: At Baseline
|
Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Time to Surgery
Aikaikkuna: At Baseline
|
Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Treated at Least Once With Neoadjuvant Therapy
Aikaikkuna: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Not Treated With Neoadjuvant Therapy
Aikaikkuna: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion
Aikaikkuna: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Trials, Hoffmann-La Roche
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- ML46477
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .